SG11201906557UA - Novel stable formulation for fxia antibodies - Google Patents
Novel stable formulation for fxia antibodiesInfo
- Publication number
- SG11201906557UA SG11201906557UA SG11201906557UA SG11201906557UA SG11201906557UA SG 11201906557U A SG11201906557U A SG 11201906557UA SG 11201906557U A SG11201906557U A SG 11201906557UA SG 11201906557U A SG11201906557U A SG 11201906557UA SG 11201906557U A SG11201906557U A SG 11201906557UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- gly
- pct
- rule
- berlin
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000015271 coagulation Effects 0.000 abstract 1
- 238000005345 coagulation Methods 0.000 abstract 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 abstract 1
- 229910000397 disodium phosphate Inorganic materials 0.000 abstract 1
- 235000019800 disodium phosphate Nutrition 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000009424 thromboembolic effect Effects 0.000 abstract 1
- 230000001732 thrombotic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17152108 | 2017-01-19 | ||
| PCT/EP2018/050951 WO2018134184A1 (en) | 2017-01-19 | 2018-01-16 | Novel stable formulation for fxia antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201906557UA true SG11201906557UA (en) | 2019-08-27 |
Family
ID=57914707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906557UA SG11201906557UA (en) | 2017-01-19 | 2018-01-16 | Novel stable formulation for fxia antibodies |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20190367636A1 (ja) |
| EP (1) | EP3570882B1 (ja) |
| JP (1) | JP7072577B2 (ja) |
| KR (1) | KR20190105588A (ja) |
| CN (1) | CN110234353B (ja) |
| AR (1) | AR110762A1 (ja) |
| AU (1) | AU2018209118A1 (ja) |
| BR (1) | BR112019014785A2 (ja) |
| CA (1) | CA3050172A1 (ja) |
| CY (1) | CY1124922T1 (ja) |
| DK (1) | DK3570882T3 (ja) |
| ES (1) | ES2904474T3 (ja) |
| HR (1) | HRP20220011T1 (ja) |
| HU (1) | HUE056858T2 (ja) |
| IL (1) | IL267917B2 (ja) |
| LT (1) | LT3570882T (ja) |
| MX (1) | MX2019008544A (ja) |
| PE (1) | PE20191476A1 (ja) |
| PL (1) | PL3570882T3 (ja) |
| PT (1) | PT3570882T (ja) |
| RS (1) | RS62780B1 (ja) |
| SG (1) | SG11201906557UA (ja) |
| SI (1) | SI3570882T1 (ja) |
| TW (1) | TWI753087B (ja) |
| WO (1) | WO2018134184A1 (ja) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200312A1 (ar) | 2015-06-26 | 2017-06-16 | Novartis Ag | الأجسام المضادة للعامل xi وطرق الاستخدام |
| TW201802121A (zh) | 2016-05-25 | 2018-01-16 | 諾華公司 | 抗因子XI/XIa抗體之逆轉結合劑及其用途 |
| AU2017383232B2 (en) | 2016-12-23 | 2024-09-12 | Novartis Ag | Factor XI antibodies and methods of use |
| MA55033A (fr) | 2019-02-18 | 2021-12-29 | Lilly Co Eli | Formulation d'anticorps thérapeutique |
| CN115003325A (zh) * | 2019-12-20 | 2022-09-02 | 安托斯治疗股份有限公司 | 因子xi/xia抗体的药物制剂和剂量方案 |
| AU2021302199A1 (en) | 2020-07-03 | 2023-02-23 | Suzhou Alphamab Co., Ltd. | Coagulation factor XI (FXI) binding protein |
| WO2022122993A1 (en) * | 2020-12-11 | 2022-06-16 | Boehringer Ingelheim International Gmbh | Formulation for multi-purpose application |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5485489B2 (ja) * | 2000-08-11 | 2014-05-07 | 中外製薬株式会社 | 抗体含有安定化製剤 |
| US20040191243A1 (en) * | 2002-12-13 | 2004-09-30 | Bei Chen | System and method for stabilizing antibodies with histidine |
| CN102159204B (zh) * | 2008-09-19 | 2015-04-01 | 辉瑞公司 | 稳定的液体抗体制剂 |
| CA2743469C (en) * | 2008-11-12 | 2019-01-15 | Medimmune, Llc | Antibody formulation |
| LT2847228T (lt) | 2012-05-10 | 2018-11-12 | Bayer Pharma Aktiengesellschaft | Antikūnai, galintys jungtis prie koaguliacijos faktoriaus xi ir (arba) jo aktyvuotos formos faktoriaus xia, ir jų panaudojimas |
| RS58856B1 (sr) * | 2013-10-25 | 2019-07-31 | Bayer Pharma AG | Nova stabilna formulacija |
-
2018
- 2018-01-16 LT LTEPPCT/EP2018/050951T patent/LT3570882T/lt unknown
- 2018-01-16 WO PCT/EP2018/050951 patent/WO2018134184A1/en unknown
- 2018-01-16 SI SI201830483T patent/SI3570882T1/sl unknown
- 2018-01-16 PE PE2019001433A patent/PE20191476A1/es unknown
- 2018-01-16 BR BR112019014785-3A patent/BR112019014785A2/pt unknown
- 2018-01-16 CA CA3050172A patent/CA3050172A1/en active Pending
- 2018-01-16 US US16/478,029 patent/US20190367636A1/en not_active Abandoned
- 2018-01-16 KR KR1020197020744A patent/KR20190105588A/ko active IP Right Grant
- 2018-01-16 MX MX2019008544A patent/MX2019008544A/es unknown
- 2018-01-16 JP JP2019538638A patent/JP7072577B2/ja active Active
- 2018-01-16 IL IL267917A patent/IL267917B2/en unknown
- 2018-01-16 PT PT187026232T patent/PT3570882T/pt unknown
- 2018-01-16 PL PL18702623T patent/PL3570882T3/pl unknown
- 2018-01-16 ES ES18702623T patent/ES2904474T3/es active Active
- 2018-01-16 CN CN201880007721.1A patent/CN110234353B/zh active Active
- 2018-01-16 EP EP18702623.2A patent/EP3570882B1/en active Active
- 2018-01-16 HU HUE18702623A patent/HUE056858T2/hu unknown
- 2018-01-16 HR HRP20220011TT patent/HRP20220011T1/hr unknown
- 2018-01-16 DK DK18702623.2T patent/DK3570882T3/da active
- 2018-01-16 RS RS20220004A patent/RS62780B1/sr unknown
- 2018-01-16 AU AU2018209118A patent/AU2018209118A1/en active Pending
- 2018-01-16 SG SG11201906557UA patent/SG11201906557UA/en unknown
- 2018-01-17 TW TW107101631A patent/TWI753087B/zh active
- 2018-01-19 AR ARP180100130A patent/AR110762A1/es unknown
-
2022
- 2022-01-05 CY CY20221100009T patent/CY1124922T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3570882A1 (en) | 2019-11-27 |
| ES2904474T3 (es) | 2022-04-05 |
| RU2019125947A3 (ja) | 2021-05-25 |
| IL267917A (en) | 2019-09-26 |
| US20190367636A1 (en) | 2019-12-05 |
| HRP20220011T1 (hr) | 2022-04-01 |
| HUE056858T2 (hu) | 2022-03-28 |
| RU2019125947A (ru) | 2021-02-19 |
| DK3570882T3 (da) | 2022-01-10 |
| IL267917B1 (en) | 2023-06-01 |
| KR20190105588A (ko) | 2019-09-17 |
| AU2018209118A1 (en) | 2019-07-11 |
| LT3570882T (lt) | 2021-12-10 |
| EP3570882B1 (en) | 2021-11-17 |
| PL3570882T3 (pl) | 2022-02-07 |
| WO2018134184A1 (en) | 2018-07-26 |
| TW201831170A (zh) | 2018-09-01 |
| SI3570882T1 (sl) | 2022-01-31 |
| JP2020506175A (ja) | 2020-02-27 |
| BR112019014785A2 (pt) | 2020-05-12 |
| RS62780B1 (sr) | 2022-01-31 |
| CY1124922T1 (el) | 2023-01-05 |
| PT3570882T (pt) | 2022-01-11 |
| TWI753087B (zh) | 2022-01-21 |
| CN110234353B (zh) | 2023-07-04 |
| PE20191476A1 (es) | 2019-10-16 |
| JP7072577B2 (ja) | 2022-05-20 |
| AR110762A1 (es) | 2019-05-02 |
| CA3050172A1 (en) | 2018-07-26 |
| MX2019008544A (es) | 2019-10-07 |
| IL267917B2 (en) | 2023-10-01 |
| CN110234353A (zh) | 2019-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201906557UA (en) | Novel stable formulation for fxia antibodies | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201908919XA (en) | Combination therapies targeting pd-1, tim-3, and lag-3 | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201811151PA (en) | Extracellular vesicle comprising a fusion protein having fc binding capacity | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201903830TA (en) | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies | |
| SG11201903021WA (en) | Anti-human 4-1 bb antibodies and use thereof | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201810697QA (en) | Chimeric antigen receptor and car-t cells that bind bcma | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201910134SA (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| SG11201811442UA (en) | Formulation of a peptide vaccine | |
| SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
| SG11201810466PA (en) | Compositions and methods related to engineered fc constructs | |
| SG11201809764XA (en) | Humanized anti-il-1r3 antibodies | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
| SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201811209QA (en) | Oral gastroretentive formulations and uses thereof | |
| SG11201806342SA (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof |